The authors' objective in this study was to identify determinants of time to discontinuation of methadone maintenance treatment (MMT) across multiple treatment episodes. Population-level data on drug dispensations for all patients receiving methadone for opioid maintenance throughout the tenure of the British Columbia, Canada, methadone program to date (1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007) were extracted from an administrative database. Proportional hazards frailty models were developed to assess factors associated with time to discontinuation from recurrent MMT episodes. A total of 17,005 patients experienced 32,656 treatment episodes over the 11-year follow-up period. Age, medical comorbidity, and physician patient load, as well as neighborhood-level socioeconomic status indicators, were significant predictors of time to discontinuation of treatment; treatment adherence and average daily doses up to and above 120 mg per day were also associated with longer treatment episodes. Studies have shown that while successfully retained in MMT, clients decrease their illicit drug use and criminal activity, and their risk of mortality is substantially lower; however, the majority of clients relapse. Many reenter treatment. The primary finding of this study was that patients experiencing multiple treatment episodes tended to stay in treatment for progressively longer periods in later episodes. heroin dependence; methadone; opioid-related disorders; proportional hazards models; survival analysis Abbreviations: CI, confidence interval; HR, hazard ratio; IQR, interquartile range; MMT, methadone maintenance treatment.
Over 40 years since its introduction as a form of opioid substitution treatment, methadone remains the most effective form of treatment for opioid dependence (1, 2) . In British Columbia, Canada, it is recommended that methadone be delivered with a maintenance-oriented philosophy, rather than an abstinence-oriented philosophy, thus acknowledging opioid dependence as a chronic disease (3) . This form of low-threshold treatment is provided by specially licensed physicians, and in most cases the methadone is dispensed and consumed at community pharmacies under direct supervision. The ineffectiveness of detoxification treatment is recognized (4) , and penalization of patients who relapse into illicit opioid use during methadone maintenance treatment (MMT) or voluntary withdrawal is discouraged (5) .
While patients are in MMT, decreases in illicit drug use, criminal activity, and mortality have all been documented (4, 6, 7) ; however, longitudinal studies of persons dependent on opioids and other drugs have generally identified patterns of chronic continued drug use, switching between periods of treatment/relapse and full abstention (8) (9) (10) (11) (12) (13) . As achievement of sustained drug abstinence has proven unattainable for the vast majority of heroin users (10) , it is of interest to determine whether long-term maintenance on substitution treatment such as methadone can be achieved among patients experiencing multiple periods of treatment and relapse.
A number of studies have focused on identifying determinants of the time to discontinuation of MMT (14, 15) ; however, none have appropriately modeled the time to discontinuation of successive treatment episodes as recurrent event data (16) . Doing so may shed light on the drug treatment careers of opioid-dependent patients and may provide evidence for making health policy decisions on appropriate treatment for patients who have failed to benefit from methadone treatment in the past.
Our objectives in this study were to identify the determinants of time to discontinuation of MMT among opioiddependent persons receiving MMT in 1 or more treatment episodes in the province of British Columbia. Historically, approximately one-half of all Canadian methadone treatment slots have been located in British Columbia (17) . To fulfill our objectives, we took advantage of a populationlevel administrative database that has collected information on methadone dispensations since 1996.
MATERIALS AND METHODS

Cohort definition
The data source for this study was the British Columbia PharmaNet database, which records all prescription drug dispensations in British Columbia. Data fields available included a deidentified patient identification number, date of birth, sex, drug identification number, date of the prescription (service date), length of the prescription (number of days for which the medication was supplied (days supplied)), drug dosage (quantity), a deidentified prescriber code and pharmacy code, and a geographic identifier, aggregated by Local Health Area. The study was approved by the University of British Columbia/Providence Health Care Behavioural Research Ethics Board.
The cohort included all persons receiving MMT over an 11-year period: January 1, 1996-December 31, 2006. MMT episodes were constructed using the service date and days supplied fields; the length of a treatment episode was calculated as the difference between the last and first days of medication dispensation ((service date t1 þ days supplied t1 ) À service date t0 ) within a period of continuous retention in treatment, where continuous treatment entailed no interruptions in prescribed doses lasting longer than 30 days. As such, we considered all treatment episodes beginning after January 30, 1996, to ensure consistency in our calculation of episode lengths and eliminate left-censored observations. Treatment episodes that were ongoing as of the end of the follow-up period were (right-) censored. Efforts were made to correct any misclassification in the data set with regard to prescribed doses, lengths, and dates of prescriptions. We found that fewer than 1% of identified errors could not be corrected.
Determinants of time to discontinuation of MMT
From the service date, days supplied, and quantity fields in the PharmaNet database, we constructed variables indicating the mean and maximum dosages over the course of a treatment episode, whether or not carry doses (take-home doses) were typically prescribed (mode of days supplied > 1), and the percentage of days on which doses were missed, or treatment adherence (calculated as the percentage of days over the duration of an episode in which methadone was dispensed). Note that this measure of adherence only considers dose administration and consequently reflects only 1 aspect of performance-adherence.
The physician code was used to construct variables indicating methadone patient load, since it is plausible that prescribers with excessively large (or small) MMT patient loads may provide suboptimal care for their patients, through either lack of individualized treatment or inexperience. Furthermore, variables indicating switches in prescribing physician and pharmacy within a treatment episode were constructed.
Information on other drugs dispensed during the 6 months prior to treatment initiation was used to construct the Clark chronic disease score (18, 19) . Clark chronic disease scores have performed well as predictors of hospitalization (20) and mortality (21) in epidemiologic research with administrative databases, suggesting that they are useful indicators of baseline comorbidity for control of confounding. A SAS macro for calculating these empirically derived comorbidity scores for patients at the time of treatment entry was modified to accommodate the Canadian Drug Product Database coding system (22, 23) . Dispensations of the majority of antiretroviral medications for human immunodeficiency virus-positive persons in the province of British Columbia were held outside of the PharmaNet database; identification of acquired immunodeficiency syndrome was therefore constructed from dispensations of prophylactic drugs.
Finally, Local Health Areas were considered urban if they included an urban center with a population greater than 50,000, and rural otherwise. Geographic data were matched with 2001 Canadian census data on income (incidence of low income), unemployment (labor force participation rate), and education (percentage of 18-year-olds without high school diplomas) (24) . Low neighborhood socioeconomic status has been shown to be associated with a variety of adverse health outcomes (25) .
Statistical analysis
The determinants of retention were analyzed using timeto-event data statistical techniques. Mantel-Haenszel tests were conducted for each independent variable considered in the analyses. Kaplan-Meier curves were plotted with respect to the key independent variables. The assumption of proportionality for each of the study variables was assessed by visual inspection of Schoenfeld residual plots and weighted residuals score tests (26) . Nonproportional hazards were accepted if the variation in b(t) was not large in comparison with the parameter estimate and the variable did not have a circular relation with the outcome. The resulting parameter estimates were therefore time-averaged regression effects. Given the simple structure of the regression model (i.e., no random effects on covariates), nonproportionality of the covariates did not bias the estimates of the variance components (27) .
Proportional hazards gamma frailty models were fitted to account for the dependence in the length of individuals' repeated treatment episodes. The proportional hazards gamma frailty model can be written as
regression coefficients. The unobserved random effect, or frailty, for the jth individual (v j ) was assumed to follow a gamma distribution (v j~c (1/h, 1/h)). Frailties are unobservable random variables corresponding to each individual's underlying modification of the baseline hazard function. They represent unobserved covariates that are common across multiple treatment episodes for each individual. Furthermore, the proportional hazards gamma frailty model captures the correlation in episode lengths within an individual; conditional on the frailty terms, the episode lengths are independent (28) . Note that while times between acute events, or ''gap times,'' have been assessed in other frailty model applications, our analysis included only durations in which patients were enrolled in continuous MMT, as described above. While the choice of time scale differs, the proportional hazards gamma frailty model can be applied in either application (29) . The covariates included in the final regression model included baseline predictors and in-treatment variables (daily dose, treatment adherence) averaged over the duration of a treatment episode; relations for the latter category should be interpreted as associations, since temporality cannot be established.
The sensitivity of parameter estimates was tested using several alternative model formulations. First, investigators in prior studies have employed different treatment discontinuation rules, and the definition used here may be subject to some degree of misclassification. The model was refitted to determine the sensitivity of parameter estimates to the length of the treatment discontinuation rule (from 30 days to 14 days or 60 days). Second, persons with numerous treatment episodes may have had different patterns of use than MMT clients with only a single attempt; it is possible that pooling these clients may have resulted in loss of information on what may be considered distinct client types with different patterns of treatment response. The proportional hazards frailty model was therefore refitted on cohorts of patients with 2-6 treatment episodes. Third, over 10% of the study cohort died during the follow-up period; inclusion of these cases may have affected the interpretation of our results. Thus, we conducted our multivariate analysis again after removing these cases to determine whether coefficient estimates remained consistent with those found in the baseline model. Finally, the outcome of later treatment attempts may have been dependent upon past treatment experiences (mean dose, adherence in episode t À 1, and the means by which episode t À 1 was discontinued-by dropout or successful taper) or the duration of time between treatment episodes. Thus, our final subanalysis considered second and subsequent treatment episodes of persons experiencing multiple treatment episodes.
The statistical analyses were executed using SAS, version 9.1 (SAS Institute Inc., Cary, North Carolina), and R, version 2.5.1 (R Foundation for Statistical Computing, Vienna, Austria (http://www.r-project.org/)). In particular, the proportional hazards gamma frailty models were fitted using R, in which the expectation-maximization algorithm was used for maximizing the partial log-likelihood function.
RESULTS
A total of 18,160 persons experienced 34,725 MMT episodes during the 11-year study period. After removal of episodes that were ongoing at the start of follow-up (n ¼ 1,715; 4.9%) and episodes in which the mean dose was less than 10 mg or more than 400 mg (indicating a high probability of coding errors) (n ¼ 354; 1.0%), our analysis included 17,005 patients. These 17,005 patients received a median of 2 treatment episodes (interquartile range (IQR), 1-3; minimum, 1; maximum, 15) during the study period, for a total of 32,656 treatment episodes.
Summary statistics on the length of time spent in treatment are presented in Table 1 . The overall median episode length was 205 days (IQR, 50-666), with 22% of all episodes ongoing at the end of follow-up. Summary statistics on all explanatory variables were generated from individuals' initial treatment episodes (captured in the PharmaNet database) and are presented in Table 2 . Thirty-four percent of all patients entering treatment were female, with the In testing the proportional hazards assumption, the null hypothesis of proportionality was rejected for most variables, as can be expected with large data sets featuring highly dispersed time-to-event lengths. Closer inspection of Schoenfeld residual plots suggested that the variation over time in most cases was small relative to the size of the timeaveraged coefficient value. The parameter estimate on treatment adherence, for instance, showed a great deal of variation over time; however, the variation was relatively small compared with the time-averaged parameter estimate, and at no point did b(t) cross zero (Figure 1 ). Three variables (carry doses prescribed, prescriber transfer, and pharmacy transfer) could be considered both predictors of the outcome and influenced by the outcome. For instance, carry doses may be more convenient for patients and thus may enhance retention, but only those clients who were successfully maintained for at least 12 weeks were recommended to be considered for carry doses (5). The parameter estimate for carry privileges accordingly twice changed direction over the length of follow-up ( Figure 2 ). These variables were therefore omitted from the model. Figures 3 and 4 show Kaplan-Meier curves for time to discontinuation of MMT stratified by treatment episode for the entire cohort and for patients experiencing at least 4 treatment episodes (generated by pooling all observations, thus not controlling for correlation between successive episodes), respectively. While later treatment episodes had a shorter median time to discontinuation overall ( Figure  3 ), among patients with multiple treatment attempts, time to discontinuation was longer in later episodes (Figure 4) . Table 3 presents the results from the proportional hazards gamma frailty model. The median frailty parameter hazard ratio for individual j (v j ) was 0.997 (IQR, 0.833-1.162; minimum, 0.221; maximum, 2.500; 50.5%). The variance of the frailty term was relatively high (0.24), and its effect was statistically significantly greater than zero (P < 0.001), indicating that significant between-subject heterogeneity was present. Conditional on the individual-specific random effect and controlling for all other covariates, later attempts at MMT had statistically significantly longer times to discontinuation (episode 2: hazard ratio (HR) ¼ 0. Furthermore, episodes featuring mean daily doses over 60 mg per day were associated with longer retention in treatment. Poor adherence to treatment had the most profound effect on retention; missing 10%-30% of prescribed doses over the course of an episode was associated with discontinuing treatment nearly 2.5 times sooner than missing fewer than 10% of prescribed doses, and persons missing more than 30% of prescribed doses discontinued treatment nearly 7 times sooner. The statistical significance of the linear time trend variable suggested that episodes initiated later in the follow-up period tended to last slightly longer, controlling for all other covariates. Patients receiving treatment from physicians with a patient load in the third quartile (89-182 patients) remained in treatment longer; however, a patient load over this level was detrimental to treatment retention. Patients with higher levels of treated comorbidity had progressively longer times to discontinuation of treatment. Finally, persons residing in neighborhoods with higher levels of low income and low educational achievement had slightly shorter times to discontinuation.
In assessing the sensitivity of our results to different model structures, we found that coefficient estimates were robust to changes in the treatment discontinuation rule and did not differ substantially after we excluded patients who died during follow-up (n ¼ 1,828 (10.7%)). Models including persons with 2-6 episodes showed that these cohorts had distinct patterns of response to treatment; however, each supported the finding that later episodes tended to be progressively longer for treatment repeaters ( Figure 5 ). Finally, among persons with at least 2 treatment episodes, the median time to treatment reentry was 143 days (IQR, 63-379), while 66.8% were classified as dropouts from their previous episode and 2.4% had successfully completed treatment, according to our definitions. Both the dose and level of adherence of the client's previous treatment episode were predictors of treatment outcome, and persons reaching abstinence in their previous episode had a longer time to discontinuation; however, coefficient estimates on the episode count variable corresponded with those generated by the baseline model, suggesting that these factors did not confound our primary results.
DISCUSSION
The primary finding of this study was that participants with multiple methadone treatment attempts were maintained for successively longer periods in later treatment attempts. Results presented in Figure 5 suggested that drug users may experience a number of failed attempts before being maintained long-term. For instance, among clients with 4-6 treatment attempts, second attempts were, at most, only marginally longer than the initial treatment episode; however, final attempts for each cohort were 85%-90% longer. Parallels to treatment for other forms of substance dependence may be drawn; for instance, in the smoking cessation literature, studies suggest that re-treating relapsed smokers with the same medication may be of substantial benefit (30, 31) . Alternative forms of treatment merit consideration as second-line options following relapse from MMT, and/or as a means of engaging patients who choose not to reenter MMT or cannot be productively maintained after numerous treatment attempts. While other forms of pharmacologic treatment have been implemented elsewhere (2, (32) (33) (34) , these were unavailable in British Columbia during the study period.
A recent Cochrane review of dosing in MMT programs could not conclude that doses greater than 100 mg per day produced better retention outcomes (35) ; however, our population-level study found no such ceiling dose threshold. Despite wide consensus on optimal dosing (36) (37) (38) , a large proportion of the participants did not receive the minimum optimal dose of 60 mg per day. Higher daily doses may also improve treatment adherence, another important determinant of retention. Emphasizing to prescribers the merits of maintaining patients on higher doses can therefore have a profound public health impact.
Another key finding was that high physician patient load had an adverse effect on treatment retention. MMT patient loads in the third quartile had a significant positive effect on episode duration, which was robust to model formulation. While our data did not include information on treatment setting, it is plausible that midsize clinical practices may produce better outcomes than practices with small MMT patient loads, and the largest clinics may not be offering responsive, individualized treatment.
We also found that progressively higher levels of treated comorbidity predicted longer treatment episodes. Given that only treated comorbidity is captured, the parameter estimates probably reflect an underlying characteristic indicating the desire and ability to acquire treatment. Receiving other prescriptions may indicate attentive or comprehensive care and therefore positively influence retention.
A person's health can be influenced by the socioeconomic characteristics of his or her neighborhood, through features of the physical, social, or service environment, by a number of pathways (25) . Using indicators that emphasized the extent of low socioeconomic status, rather than measures of central tendency, we found that participants residing in neighborhoods with lower high school completion rates were retained in treatment for shorter durations.
Application of the proportional hazards gamma frailty modeling technique allowed us to utilize all data available to us, rather than focus on a single treatment episode. Furthermore, application of proportional hazards gamma frailty models allowed for accurate inference into the effects of successive episodes through the use of the individualspecific frailty term, which takes into account the correlation between repeated episodes of treatment and captures unobserved heterogeneity across individuals. Researchers in 2 prior studies have acknowledged the recurrent nature of MMT but have chosen to model these effects by calculating standard errors robust to the individual-level clusters, rather than acknowledge the true longitudinal nature of the data (39, 40) . It is crucial to note that these techniques cannot incorporate the correlation among successive observations for an individual entity and thus may provide biased parameter estimates when used in applications with repeated measures across individuals. Given the effect of model formulation on coefficient estimates (specifically on the episode count variable, which was reversed in a previous study), this was an important innovation in the analysis of MMT data. While frailty models have scarcely been used in applied studies, these methods may be useful in any study of diseases with periods of remission and relapse, including cancer, autoimmune diseases, and other forms of substance dependence (29) .
Our study was not without limitations. First, our results primarily reflect the treatment careers of opioid-dependent persons with free access to primarily low-threshold, community-based methadone treatment programs. Second, some proportion of the study sample may have been lost to follow-up because of intraprovincial outmigration; past studies of injection drug users in Vancouver, British Columbia, suggest that this proportion is small (1.2%-5.5% per year) (41) . This can be considered nondifferential outcome misclassification, resulting in attenuation of measures of association towards the null value, which suggests that our hazard ratios may have been somewhat conservative. Third, retention in treatment is necessarily an intermediate outcome; while the benefits of MMT are only experienced while in treatment, other outcomes, including opioid abstinence, were not captured. The data presented here relate only to the duration of medication administration.
Finally, there were both advantages and disadvantages in using administrative data to conduct this retrospective cohort study. The primary limitations were 2-fold: First, there was potential for misclassification of treatment episode lengths, dosage, and adherence because of coding errors in the database. As described above, we took steps to reduce this misclassification as much as possible. Second, results from any nonexperimental study may be subject to residual and/or unmeasured confounding (42) . Data on other predictors of retention in treatment such as use of other illicit drugs, criminal activity, motivational status, and social supports were unavailable. Though we cannot ascertain the individual effects of the unobserved factors, we can confidently state that their omission did not bias the coefficients on the existing fixed effects included in the analysis. The advantages of using this data set, however, were substantial: The use of this centralized drug dispensation database allowed for a population-level study unparalleled in size, which allowed us to observe not only the effects of several key determinants on individual episodes but also the pattern of treatment, thus taking into account the chronic, recurrent nature of opioid dependence. We believe our findings add considerable insight into the study of patients' drug treatment careers (43) by capturing the natural patterns of remission and relapse exhibited by opioid-dependent persons.
In a population-level study of more than 17,000 patients carried out over an 11-year period, we found that methadone can be an effective form of treatment for opioid dependence, even among persons who have been unsuccessful in the past. The prescription of higher daily doses of methadone and improvements in adherence can improve treatment retention substantially.
